Trial Profile

A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Toripalimab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

10 Mar 2023 Status changed from active, no longer recruiting to recruiting.
09 Mar 2023 Planned End Date changed from 1 Feb 2028 to 1 Mar 2028.
09 Mar 2023 Planned primary completion date changed from 1 Feb 2025 to 1 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com